In this episode, I’ll discuss the use of sugammadex in myasthenia gravis patients undergoing thymectomy.
A group of authors in Japan recently analyzed the association between the use of sugammadex and postoperative myasthenic crisis in patients with myasthenia gravis using a national inpatient database.
506 patients who received sugammadex were compared with 289 controls who did not receive sugammadex.
The sugammadex group was associated with a decrease in postoperative myasthenic crisis with an odds ratio of 0.48.
The sugammadex group also had a shorter median length of hospital stay by 1 day than the control group and a corresponding $1000 lower total cost of care.
The authors concluded that their study indicates that sugammadex should be used for MG patients who receive thymectomy for reversal of muscle paralysis after surgery rather than anticholinesterase.
The study does not provide any details on the use of neuromuscular blocking agents between groups, including the agent or dose used. The study is based on coded data of patients who received sugammadex for NMBA reversal, but additional data on the NMBAs and doses used would be nice to have.
Members of the Hospital Pharmacy Academy have access to a practical training from a pharmacist’s point of view about the use of sugammadex, in addition to hundreds of other practice resources. From the time of this recording until 10 pm EST on Tuesday, April 25, you can get a special recurring quarterly membership of 3 months for the price of 2 to the Hospital Pharmacy Academy. To get immediate access, go to pharmacyjoe.com/quarterly. Current monthly members of the Hospital Pharmacy Academy can also access this discount by going to their member profile page at pharmacyjoe.com/profile.
If you like this post, check out my book – A Pharmacist’s Guide to Inpatient Medical Emergencies: How to respond to code blue, rapid response calls, and other medical emergencies.